综合医疗机构结核潜伏感染高危人群结核病预防性治疗专家共识
该共识由中华医学会呼吸病学分会和国家呼吸医学中心组织专家制定,针对综合医疗机构中结核病发病高危的潜伏结核感染(LTBI)人群,提出19条循证推荐。推荐涵盖需筛查和预防性治疗(TPT)的目标人群(HIV感染/AIDS 1B、TNF-α拮抗剂治疗 1C、长期透析 1D、计划器官/骨髓移植 1C、矽肺 1D、长期糖皮质激素或免疫抑制剂 1D、辅助生殖不孕女性 2D),并明确各人群的TPT时机与方案(如HIV感染者6H、9H、3HR、3H2P2 1A;TNF-α拮抗剂3HR/3H2P2 1B;透析6H首选2B;移植9H 1B;矽肺6H 1D;糖皮质激素/免疫抑制剂3H2P2 1B等)。共识强调综合临床评估后排除活动性结核再启动TPT,为综合医疗机构规范实施TPT提供指导。
要点
- 综合医疗机构中建议进行LTBI检测和TPT的人群包括:HIV感染/AIDS(1B)、TNF-α拮抗剂治疗(1C)、长期血液透析/腹膜透析(1D)、计划器官或骨髓移植(1C)、矽肺(1D)、长期使用糖皮质激素或其他免疫抑制剂(1D)、接受辅助生殖的不孕女性(2D)。
- HIV感染/AIDS合并LTBI者应尽快启动TPT,无论是否已开始抗逆转录病毒治疗(1B);可选6H、9H、3HR和3H2P2方案(1A);MTB暴露高风险者推荐异烟肼单药36个月或更长(1B)。
- 使用TNF-α拮抗剂合并LTBI者推荐3HR和3H2P2方案(1B);有联合用药禁忌或药物性肝损伤者可选用6H(1B),必要时TPT疗程可延长至6个月(1C);非紧急状态可在TPT 4周后开始TNF-α拮抗剂(1C),紧急状态可同时给药(1C)。
- 长期血液透析或腹膜透析合并LTBI者首选6H方案(2B),根据依从性可选用3HR或3H2P2(2D);腹膜透析按常规剂量给药、不受给药时间影响,血液透析推荐透析结束后给药(1D)。
- 计划器官或骨髓移植合并LTBI者推荐9H方案(1B);移植前建议筛查供者LTBI,供者阳性时受者建议TPT(1D);TPT不必在移植前完成,因移植中断者病情稳定后应尽快恢复(1D);肝移植后需TPT者建议肝功能稳定后进行(1D)。
适用人群与场景
- 综合医疗机构中结核病发病高危的LTBI人群:HIV感染/AIDS患者(1B)、接受TNF-α拮抗剂治疗者(1C)、长期血液透析/腹膜透析者(1D)、计划接受器官移植或骨髓移植者(1C)、矽肺患者(1D)、长期使用糖皮质激素或其他免疫抑制剂者(1D)、接受辅助生殖的不孕女性(2D)。
- 长期口服糖皮质激素定义为泼尼松等效剂量≥15 mg/d且持续超过4周(推荐17、18)。
- 计划器官或骨髓移植的受者,移植前建议筛查供者LTBI(推荐13)。
诊断标准与关键阈值
- 对综合医疗机构TPT目标人群,应选择合适的诊断技术检测MTB感染,排除活动性结核后,经综合临床评估对LTBI者建议TPT(1D)。
- 长期口服糖皮质激素的TPT启动阈值为泼尼松等效剂量≥15 mg/d且持续超过4周(推荐17、18)。
- 接受辅助生殖的不孕女性应进行LTBI检测;潜伏生殖道结核者推荐按活动性结核治疗方案行TPT;LTBI且生殖系统样本结核核酸检测阴性者推荐6H方案(2D)。
处置流程与药物剂量
- HIV感染/AIDS合并LTBI者应尽快启动TPT,无论是否已开始抗逆转录病毒治疗(1B);可选6H、9H、3HR和3H2P2方案(1A);MTB暴露高风险者推荐异烟肼单药36个月或更长(1B)。
- 使用TNF-α拮抗剂合并LTBI者推荐3HR和3H2P2方案(1B);有联合用药禁忌或药物性肝损伤者可选用6H(1B),必要时根据TNF-α拮抗剂疗程将TPT延长至6个月(1C);非紧急状态可在TPT 4周后开始TNF-α拮抗剂(1C),紧急状态可同时给药(1C)。
- 长期血液透析或腹膜透析合并LTBI者首选6H方案(2B),根据依从性可选用3HR或3H2P2(2D);腹膜透析按常规剂量给药、不受给药时间影响,血液透析推荐透析结束后给药(1D)。
- 计划器官或骨髓移植合并LTBI者推荐9H方案(1B);TPT不必在移植前完成,因移植中断者病情稳定后应尽快恢复(1D);肝移植后需TPT者建议肝功能稳定后进行(1D)。
- 矽肺合并LTBI者推荐6H方案(1D)。
- 长期口服糖皮质激素(泼尼松等效剂量≥15 mg/d且超过4周)或其他免疫抑制剂合并LTBI者,综合临床评估后推荐3H2P2方案;有联合用药禁忌者可选用6H或9H(1B);TPT启动时机由原发病状态决定,条件允许时推荐在启动糖皮质激素或其他免疫抑制治疗前优先给予TPT 1个月(2D)。
- 接受辅助生殖的不孕女性:潜伏生殖道结核者按活动性结核治疗方案行TPT;LTBI且生殖系统样本结核核酸检测阴性者推荐6H方案(2D)。
研究设计与关键结果
- 中华医学会呼吸病学分会和国家呼吸医学中心组织专家,针对综合医疗机构结核病发病高危人群TPT的对象界定、治疗时机和治疗方案,在循证医学基础上形成19条具有指导性的专家推荐意见。
证据类型、等级与局限
- 证据类型:专家共识;推荐意见采用 GRADE 分级(1A、1B、1C、1D、2B、2D 等),共19条推荐。
- 局限:原文未报告局限性。
对床旁实践的改变
- 综合医疗机构应对HIV感染/AIDS、使用TNF-α拮抗剂、长期透析、计划器官/骨髓移植、矽肺、长期使用糖皮质激素或免疫抑制剂及接受辅助生殖的不孕女性等LTBI高危人群开展筛查,排除活动性结核并综合评估后建议TPT(1D)。
- HIV感染/AIDS合并LTBI者应尽快启动TPT,不必等待抗逆转录病毒治疗开始(1B);MTB暴露高风险者推荐异烟肼单药36个月或更长(1B)。
- 使用TNF-α拮抗剂合并LTBI者,非紧急状态可在TPT 4周后开始TNF-α拮抗剂,紧急状态可同时给药(1C)。
- 血液透析合并LTBI者推荐透析结束后给药(1D);腹膜透析按常规剂量给药、不受给药时间影响。
- 计划器官或骨髓移植合并LTBI者推荐9H方案(1B);TPT不必在移植前完成,因移植中断者病情稳定后应尽快恢复(1D);肝移植后需TPT者建议肝功能稳定后进行(1D)。
- 长期口服糖皮质激素(泼尼松等效剂量≥15 mg/d且超过4周)或其他免疫抑制剂合并LTBI者,条件允许时推荐在启动糖皮质激素或其他免疫抑制治疗前优先给予TPT 1个月(2D)。
指南或共识出处
- 中华医学会呼吸病学分会、国家呼吸医学中心组织制定的《综合医疗机构结核潜伏感染高危人群结核病预防性治疗专家共识》,发表于《中华结核和呼吸杂志》。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Promoting tuberculosis preventive treatment (TPT) for individuals with latent tuberculosis infection (LTBI) who are at high risk of developing active tuberculosis (TB) is an important tool for accelerating the decline in TB incidence and achieving the global goals of the End TB strategy. As a country with a high burden of TB, China has implemented patient-centred strategies in the past, but TPT has not been systematically implemented. In the comprehensive medical facilities, there are many types of TPT target populations and their health situation is complex, which poses more challenges for TPT implementation. To improve the work of TPT in comprehensive medical institutions, experts organized by the Chinese Medical Association Respiratory Branch and the National Respiratory Medicine Center made the following evidence-based recommendations on the identification of TPT targets and the selection of TPT timing and regimen.Recommendation 1: Based on comprehensive clinical evaluation, patients in comprehensive medical facilities who are recommended to undergo LTBI testing and TPT include: HIV infections/AIDS patients (1B), patients treated with TNF-α antagonists (1C), patients receiving long-term hemodialysis/peritoneal dialysis (1D), patients planning to receive organ transplantation or bone marrow transplantation (1C), patients with silicosis (1D), patients using glucocorticoids or other immunosuppressants for a long-time (1D), infertile women receiving assisted reproduction (2D).Recommendation 2: For TPT target populations in comprehensive medical facilities, an appropriate diagnostic technology should be selected to test for MTB infection. After exclusion of active TB, TPT should be suggested to people with LTBI after comprehensive clinical evaluation (1D).Recommendation 3: In HIV infections/AIDS patients with LTBI, TPT should be started as soon as possible regardless of whether antiretroviral treatment has been initiated (1B).Recommendation 4: 6H, 9H, 3HR and 3H2P2 regimens could be used in HIV-HIV infections/AIDS patients with LTBI (1A).Recommendation 5: For HIV infections/AIDS patients at high risk of MTB exposure, it is recommended to use isoniazid alone for 36 months or longer for TPT (1B).Recommendation 6: In patients treated with TNF-α antagonists and with LTBI, 3HR and 3H2P2 regimen is recommended for TPT (1B).Recommendation 7: In patients treated with TNF-α antagonists and with LTBI, 6H regimen can be used as an alternative for those with contraindications to combined medication or drug-induced liver injury (1B). If necessary, the TPT cycle can be extended to 6 months, depending on the course of TNF-α antagonist use (1C).Recommendation 8: In patients treated with TNF-α antagonists and with LTBI, the timing of TPT should be based on clinical assessment. TNF-α antagonist treatment can be started 4 weeks after TPT in non-urgent disease states (1C), and can be given concomitantly in emergency states (1C).Recommendation 9: For patients who receive long-term hemodialysis or peritoneal dialysis and with LTBI, 6H regimen is recommended as the preferred regimen for TPT (2B).Recommendation 10: For patients who receive long-term hemodialysis or peritoneal dialysis and with LTBI, 3HR or 3H2P2 regimen can be used as alternatives based on clinical evaluation according to patient compliance (2D).Recommendation 11: The timing of TPT varies according to different dialysis methods: in patients on peritoneal dialysis, TPT is administered at regular doses and is not affected by the timing of administration; in patients on hemodialysis, it is recommended to administer after the completion of hemodialysis (1D).Recommendation 12: For recipients who are planning to receive organ transplantation or bone marrow transplantation and with LTBI, 9H regimen is recommended for TPT (1B).Recommendation 13: Prior to organ transplantation or bone marrow transplantation, it is recommended to screen the donor for LTBI. If the donor is LTBI positive, the recipient should be suggested for TPT (1D).Recommendation 14: For recipients who are planning to receive organ or bone marrow transplantation, TPT does not have to be completed before transplantation. TPT interrupted because of transplantation should be resumed as soon as possible when the condition is stable (1D).Recommendation 15: In patients who have undergone liver transplantation, if TPT is required, it is recommended to be carried out when post-transplant liver function is stable (1D).Recommendation 16: In silicosis patients with LTBI, 6H regimen is recommended for TPT (1D).Recommendation 17: For patients on long-term oral glucocorticoids (prednisone equivalent dose≥15 mg/d for more than 4 weeks) or other immunosuppressants and with LTBI, based on comprehensive clinical evaluation, 3H2P2 regimen is recommended for TPT. In patients with contraindications to combined medication, 6H or 9H can be used as an alternative (1B).Recommendation 18: In patients taking long-term oral glucocorticoids (prednisone equivalent dose≥15 mg/d for more than 4 weeks) or use other immunosuppressants and with LTBI, the timing of initiation of TPT should be determined by the status of the primary disease. If the condition permits, it is recommended to give priority to TPT for one month before initiating glucocorticoid or other immunosuppressive therapy (2D).Recommendation 19: It is recommended that infertile women undergoing assisted reproduction should undergo LTBI testing. For those with latent genital TB, TPT is recommended using regimen for active TB treatment. For those with LTBI and reproductive system samples that are negative for TB nucleic acid testing, 6H regimen is recommended for TPT (2D).
针对发病高风险的结核潜伏感染者开展结核病预防性治疗,是实现终结结核病流行全球战略目标的重要手段。作为结核病高负担国家,我国既往的结核病防治更多侧重患者的主动发现和规范治疗,尚未系统开展预防性治疗工作。综合医疗结构所涉及的结核病发病高危人群类型多、情况复杂,开展结核病预防性治疗及其管理难度较大。为推动综合医疗机构结核病预防性治疗工作的实施,中华医学会呼吸病学分会和国家呼吸医学中心牵头组织相关专家,针对综合医疗机构结核病发病高危人群预防性治疗对象的界定、治疗时机、治疗方案等临床问题,在循证医学基础上形成19条具有指导性的专家推荐意见,供综合医疗机构的医务工作者在临床工作中参考和实践。.
参考来源
- [Expert consensus on tuberculosis preventive treatment for individuals at high risk of developing active diseases from latent tuberculosis infection in comprehensive medical facilities]. Zhonghua Jie He He Hu Xi Za Zhi. 2024. PMID: 39406540. doi:10.3760/cma.j.cn112147-20240328-00173
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。